FMP
Cassava Sciences, Inc.
SAVA
NASDAQ
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
2.37 USD
0.025 (1.06%)
About
ceo
Mr. Richard Jon Barry
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
CIK
0001069530
ISIN
US14817C1071
CUSIP
14817C107
Address
7801 North Capital of Texas Hi...
Phone
512 501 2444
Country
US
Employee
29
IPO Date
Jul 14, 2000
Key Executives
